Niagen Bioscience, Inc. · NASDAQ:NAGE
Niagen Bioscience — ChromaDex — Q1 2021 Earnings Presentation
23 slides from Niagen Bioscience's earnings presentation, May 6, 2021
Slide 1: Earnings Conference Call First Quarter 2021
TRU NIAGEN ChromaDex Earnings Conference Call First Quarter 2021 Rob Fried Chief Executive Officer Frank Jaksch Co-Founder / Executive Chairman Kevin Farr Chief Financial Officer Nasdaq: CDXC | May 6, 2021 1
Slide 2: S croman TRUNIAGEN
S croman TRUNIAGEN
Slide 3: Q1 2021 & Recent Highlights
Q1 2021 & Recent Highlights Tru Ni sequent sn net sales up 12% and total company up 2% YoY. Tru Niagen® net sales up 1% and total company down 5% lly. Supply chain disruptions impacted Watsons’ shipments, which are expected to normalize in Q2 and Q3. Net loss was ($7.4) million or ($0.12) per share,
Slide 4: Management Team
Management Team TRU NIAGEN
Slide 5: Scientific Update
Scientific Update
Slide 6: Scientific Advisory Board
Scientific Advisory Board
Slide 7: Most prominent human clinical research areas for Niagen
Most prominent human clinical research areas for Niagen® are vitality, locomotion, cognition, and sensory ‘sexe fees pa Tega us Cogn moment “ecco concen Caceres | Aimar Outen Sma a Fi noon, Nemec Fat ne” tac Franson Woetons sweiena rene ay Oana wen: adc Nag? WB leech oad Conse a an vat ade 8 wages n
Slide 8: NR Research Impact is Accelerating
NR Research Impact* is Accelerating = = @ & ‘Basic Research ‘Cumulative impact Factor eRe monty domains tines Cass 2013 2014 2015-2016 2017208 201920202024
Slide 9: Science Continues to Expand
Science Continues to Expand + Two new human stud ‘on nicotinamide riboside registered since prior update: ‘+ Massachusetts General Hospital and Harvard Medical School (March 2021) ‘+ The objective is to investigate the impact of NR supplementation in 100 patients with persistent cognitive and physic
Slide 10: Financial Highlights
Financial Highlights
Slide 11: Q1 2021 Net Sales Mix
Q1 2021 Net Sales Mix Q1 2020 12021 $14.3MM * $14.7MM “— _ vt gent ‘tne ngs, seonandenoee as > Tru Niagen® net sales increased to 85% of net sales in Q1 2021 compared to 80% in Q4 2020 > Niagen®-related net sales decreased to 93% of net sales in Q1 2021 compared to 94% in Q 2020 °) Higher mix of Tru
Slide 12: Q1 2021 Net Sales
Q1 2021 Net Sales Q1 2021 Net Sales Growth Rates (6 in millions) YoY % 00 % (ws 2020)—_(vs.042020) wore aone oro I 2° nn heen reat! 08 ‘Standards 8 Services (1) Other ingredients | 0.1
Slide 13: 2018 — 2021 YTD Net Sales Summary
2018 — 2021 YTD Net Sales Summary 993) 399 33° 995 Pe PE 289) 335
Slide 14: Q1 2021 vs Q4 2020 Key P&L Metrics
Q1 2021 vs Q4 2020 Key P&L Metrics (eo emande) Pat zoat | atzoe0 [notes Tru Nagen® business up 1% seven by gabal e-Commerce and Net Sates sages sasaas_— einen ces, oy ey ve een Sslesowerance nlangesoing 9 Thome. ‘Up 1800p erivenby predict cost savings inten, ver sal Gross Profit 9.234 ton supp ena o
Slide 15: Q1 2021 vs Q1 2020 Key P&L Metrics
Q1 2021 vs Q1 2020 Key P&L Metrics “Tru Nagon® bunness up 12% wth roan n ebal ecommerce andtecenttematonaaunehes. Watsons sales down sgh) Netsaies $1445 Given by COVID-19 supp chan eruptions and chalengg por Ig ear compare (eta snpsinfrTruNlagen® Beauty inst) Gross Profit tant Seling and Marketing N
Slide 16: Adjusted EBITDA Summary
Adjusted EBITDA Summary Reconciliation of Non GAAP Financial Measures (thousands) War Si, Wn30, Sep 30, Dee 3H, | Mardi, an 30, Sop 30, Owe 3H, | Mah zoo “zoi_t019" 2010" | “2020' _“20m0' “20002000 | 2024 Netios, a reported 5 33 $ @.788) $0202) $ easy |s 69) s a7 $4218) $ (os |s Cae “Adusets ‘ree (r
Slide 17: Q1 2021 Operating Loss vs Q1 2020
Q1 2021 Operating Loss vs Q1 2020 TRU NIAGEN
Slide 18: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights Ge 23s | xciie| sain | sooo | enzo | rasico | att | Key Driver 525 mln eaptlrase plus $2261 $1mei2 515008 $10.800 515.478 | SHEET | $4460 sock optoncnercney employees 1230811001 RES) 12.702 _lovosmeniato support Sos 3208 | 264 | 4647 sales nating ot 52i8 5.73 | 6AB
Slide 19: Quarterly Cash Flow Highlights
Quarterly Cash Flow Highlights (thousands) Fy 2018 | FY 2019 9730720 S069) $@7) $4218) —_$(6.007) $0620) $528 saat S219 Sars 13600 s1ms90 ssaTe 16697 Investments to grow the business and protect our IP, while tightly managing working (been tn tres ten er payee a Nes {2 nove tomar asses comets rie me
Slide 20: 2021 Financial Outlook
2021 Financial Outlook Contnued sendy revenue growth, + Glabsl e-Commerce business ‘wen acelerata grontnin G2 2021 | Exstng + new evatege partnerships Net Stee sez s80257 ‘Gross Margin % 57% (8a Kotnet aos) ‘Seling, Marketing & Advertising 394% 384% Up sghty an 0% of net sales (asa otnet sates) Rese
Slide 21: Adjusted EBITDA 2019 vs 2020
Adjusted EBITDA 2019 vs 2020 Chromabex Corporation and Sass (nttowsend) Vearended Year oer Yor Neth a sep Inet eee n Dacca oy Amer fangs ea) ‘Amount gif we sete » ‘Saretunedconpemat ron Seven and eretng 1790 vamebiod tad St perc : Adel EBEIDA z Tag Tealepeageme as Adin EBITDA cna a pl ene ano saan,
Slide 22: Q1 2021 Financial Highlights - Recap
Q1 2021 Financial Highlights - Recap ‘Total net sales of $14.7 million in Qt 2021 (+2% YoY, -5% versus 4 2020) Demonstrated continued progress building Tru Niagen® into a global brand ‘+ Tru Niagen® net sales of $12.4 milion in Q1 2021 (+12% YoY) *+ Continued sequential growth in Tru Niagen® net sal
Slide 23: Contact Info
Contact Info Brianna Gerber Vice President of Finance and Investor Relations T: +1.949.419.0288 ext. 127 BriannaG@chromadex.com www.chromadex.com Where to buy TRU NIAGEN® ynmw.truniagen,com www.amazon.com